All rights reserved. No reuse allowed without permission.

Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort

Authorship:

Alex Handy¹, Amitava Banerjee¹⁻³, Angela Wood⁴⁻⁸, Caroline E Dale¹, Cathie Sudlow⁹⁻¹¹, Christopher Tomlinson^{1,2,12,13}, Daniel Bean¹⁴⁻¹⁶, Johan H Thygesen¹, Mehrdad A Mizani¹, Michail Katsoulis¹, Reecha Sofat¹, Richard Dobson^{1,13-16}, Rohan Takhar¹, Sam Hollings¹⁷, Spiros Denaxas^{1,13,18}, Venexia Walker¹⁹, on behalf of the CVD-COVID-UK Consortium

- 1. Institute of Health Informatics, University College London, London, UK.
- 2. University College London Hospitals NHS Trust, London, UK
- 3. Barts Health NHS Trust, The Royal London Hospital, London, UK
- 4. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- 5. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
- 6. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
- 7. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
- 8. The Alan Turing Institute, London, UK
- 9. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- 10. British Heart Foundation Data Science Centre, Health Data Research UK, London, UK
- 11. Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
- 12. UKRI Centre for Doctoral Training in Al-enabled Healthcare Systems, University College London, London, UK
- 13. National Institute for Health Research University College London Hospitals Biomedical Research Centre, University College London, London, UK
- 14. NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Trust, London, UK.
- 15. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- 16. Health Data Research UK London, University College London, London, UK
- 17. NHS Digital, Leeds, UK
- 18. British Heart Foundation Research Accelerator, University College London, London, UK
- 19. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Correspondence to Alex Handy, <u>a.handy@ucl.ac.uk</u>, Institute of Health Informatics, University College London, 222 Euston Rd, London NW1 2DA, UK

Word count (excluding title page, abstract, key questions, acknowledgments, competing intereste with a line of the second state of the second stat

ABSTRACT

Objective

Evaluate antithrombotic (AT) use in individuals with atrial fibrillation (AF) and high stroke risk (CHA₂DS₂-VASc score>=2) and investigate whether pre-existing AT use may improve COVID-19 outcomes.

Methods

Individuals with AF and a CHA₂DS₂-VASc score>=2 on January 1st 2020 were identified using pseudonymised, linked electronic health records for 56 million people in England and followed-up until May 1st 2021. Factors associated with pre-existing AT use were analysed using logistic regression. Differences in COVID-19 related hospitalisation and death were analysed using logistic and Cox regression for individuals exposed to pre-existing AT use vs no AT use, anticoagulants (AC) vs antiplatelets (AP) and direct oral anticoagulants (DOACs) vs warfarin.

Results

From 972,971 individuals with AF and a CHA₂DS₂-VASc score>=2, 88.0% (n=856,336) had pre-existing AT use, 3.8% (n=37,418) had a COVID-19 related hospitalisation and 2.2% (n=21,116) died. Factors associated with no AT use included comorbidities that may contraindicate AT use (liver disease and history of falls) and demographics (socioeconomic status and ethnicity). Pre-existing AT use was associated with lower odds of death (OR=0.92 *[0.87-0.96 at 95% CI]*), but higher odds of hospitalisation OR=1.20 *[1.15-1.26 at 95% CI]*). The same pattern was observed for AC vs AP (death (OR=0.93 [0.87-0.98]), hospitalisation (OR=1.17 [1.11-1.24])) but not for DOACs vs warfarin (death (OR=1.00 [0.95-1.05]), hospitalisation (OR=0.86 [0.82-0.89]).

Conclusions

Pre-existing AT use may offer marginal protection against COVID-19 death, with AC offering more protection than AP. Although this association may not be causal, it provides further incentive to improve AT coverage for eligible individuals with AF.

KEY QUESTIONS

What is already known about this subject?

- Anticoagulants (AC), a sub-class of antithrombotics (AT), reduce the risk of stroke and are recommended for individuals with atrial fibrillation (AF) and at high risk of stroke (CHA₂DS₂-VASc score>=2, National Institute for Health and Care Excellence threshold). However, previous evaluations suggest that up to one third of these individuals may not be taking AC. Over estimation of bleeding and fall risk in elderly patients have been identified as potential factors in this under medicating.
- In response to the COVID-19 pandemic, several observational studies have observed correlations between pre-existing AT use, particularly anticoagulants (AC), and lower risk of severe COVID-19 outcomes such as hospitalisation and death. However, these correlations are inconsistent across studies and have not compared all major sub-types of AT in one study.

What does this study add?

- This study uses datasets covering primary care, secondary care, pharmacy dispensing, death registrations, multiple COVID-19 diagnoses routes and vaccination records for 56 million people in England and is the largest scale evaluation of AT use to date. This provides the statistical power to robustly analyse targeted sub-types of AT and control for a wide range of potential confounders. All code developed for the study is opensource and an updated nationwide evaluation can be rapidly created for future time points.
- In 972,971 individuals with AF and a CHA2DS2-VASc score>=2, we observed 88.0% (n=856,336) with pre-existing AT use which was associated with marginal protection against COVID-19 death (OR=0.92 [0.87-0.96 at 95% CI]).

How might this impact on clinical practice?

 These findings can help shape global AT medication policy and provide population-scale, observational analysis results alongside gold-standard randomised control trials to help assess whether a potential beneficial effect of pre-existing AT use on COVID-19 death alters risk to benefit assessments in AT prescribing decisions.

INTRODUCTION

Atrial fibrillation (AF) is a disturbance of heart rhythm affecting 37.5 million people globally[1] and significantly increases stroke risk[2]. Anticoagulants (AC), a sub-type of antithrombotics (AT), reduce the risk of stroke[3] and are recommended for individuals with AF and a high risk of stroke (CHA2DS2-VASc score>=2, National Institute for Health and Care Excellence (NICE) threshold)[4,5]. Despite improvements in AC uptake, previous evaluations suggest that up to one third of individuals with AF and a CHA2DS2-VASc score>=2 in the UK may not be on AC[6], with around 15% on no type of AT[6]. Hypotheses for this sub-optimal medication centre around clinical over estimation of bleeding and fall risk in elderly patients[6,7] but the potential drivers of AT use remain under explored at population scale.

COVID-19 has presented another risk factor for individuals with AF, who are at increased risk of poor outcomes if they become infected[8]. Observational evidence from Germany (n=6,637) suggests that pre-existing AC use, but not antiplatelets (AP - another sub-type of AT), may reduce mortality for individuals hospitalised with COVID-19[9]. However, evidence is discordant with a US study (n=3,772) observing no difference in mortality in groups on AC or AP[10]. In the UK, a larger study (n = 70,464 / 372,746) explored AC and AC sub-types (warfarin vs direct oral anticoagulants (DOACs)) in individuals with AF and observed that AC was associated with a lower COVID-19 specific mortality[11]. This observational evidence is promising, but it does not compare all sub-types of AT and only covered the period up to September 28th 2020.

This study, therefore, set out to conduct the largest scale evaluation of AT use in individuals with AF to date in routinely updated, linked, population-scale electronic health record (EHR) data for 56 million people in England[12]. Utilising this statistical power, this study investigated what factors are associated with pre-existing AT use and whether pre-existing AT use (across sub-types) may reduce COVID-19 related hospitalisation and death.

METHODS

Study design and data sources

We conducted a cohort analysis using the newly established NHS Digital Trusted Research Environment (TRE) for England which provides secure, remote access to linked, person level EHR data for over 56 million people[12]. Available data sources cover primary care, secondary care, pharmacy dispensing, death registrations and COVID-19 tests and vaccines. For this study, we used the General Practice Extraction Service Extract for Pandemic Planning and Research (GDPPR) for demographic and diagnostic data (e.g. a diagnosis of AF) and the NHS Business

Service Authority Dispensed Medicines (BSADM) for medication exposure data (e.g. pre-existing AT use) as this is the most accurate available representation of the medication an individual takes. Hospital Episode Statistics (HES), COVID-19 Hospitalisations in England Surveillance System (CHESS), Secondary Uses Service (SUS) and Office for National Statistics (ONS) Civil Registration of Deaths were used for COVID-19 hospitalisation and death. Public Health England's Second Generation Surveillance System (SGSS) was used to identify COVID-19 test results and the COVID-19 vaccination events dataset was used for COVID-19 vaccine status.

Figure 1 provides an illustrative overview of how cohorts were designed to address the study objectives and the open protocol (<u>https://github.com/BHFDSC/CCU020/tree/main/england/protocol</u>) provides an overview, including all protocol amendments.

Study populations

Individuals were included in the study if registered with a GP practice in England (at least one record in the GDPPR dataset with a valid person pseudo identifier), >= 18 years old and alive on January 1st 2020, had available sex, ethnicity and GP practice location data (based on most recent, available data across primary care (GDPPR), secondary care (HES) and death registrations (ONS)) and had a diagnosis of AF (coded in GDPPR) with a CHA₂DS₂-VASc score>=2 (calculated from the sum of components[13] coded in GDPPR).

Individuals with contraindications for sub-types of AT (e.g. DOACs in mitral stenosis, prosthetic mechanical valves, antiphospholipid antibody syndrome) were included as they are still eligible for other AT sub-types (e.g. AP, warfarin).

To investigate exposure to pre-existing AT use on COVID-19 related hospitalisation and death, inclusion criteria of a recorded COVID-19 event were applied. A COVID-19 event was defined as any of a positive test (polymerase chain reaction or lateral flow), a coded diagnosis in primary or secondary care or a COVID-19 diagnosis on a death certificate (see Thygesen et al

(https://github.com/BHFDSC/CCU013 01 ENG-COVID-

<u>19 event phenotyping/tree/main/phenotypes</u>) for further details and phenotyping algorithms).

All phenotyping algorithms used are available on Github (<u>https://github.com/BHFDSC/CCU020/tree/main/england/phenotypes</u>). *Supplementary Figure 1* provides an overview of the numbers of individuals excluded at each stage.

Study variables

Medication exposure

An individual was defined as taking a particular medication if they had >=1 dispensed prescription (coded in the NHS BSADM) in the previous 6 months. We purposefully defined a liberal threshold to support evaluation of AT usage up to May 2021 that may have included unusual buying patterns (e.g. bulk buying) caused by the pandemic.

Mutually exclusive medication categories were constructed for AC only, AP only, AP and AC and no AT. Apixaban, rivaroxaban, dabigatran and edoxaban were collectively categorised as DOACs for comparison with warfarin. For analysis, three mutually exclusive medication categories were tested (any AT vs no AT, AC only vs AP only, DOACs vs warfarin).

Outcomes

We defined two COVID-19 outcomes, COVID-19 related hospitalisation and COVID-19 death. COVID-19 hospitalisation included any hospital admission with a recorded COVID-19 diagnosis in any position (e.g. not the primary diagnosis). COVID-19 death included individuals with a COVID-19 diagnosis on their death certificate in any position, a registered death within 28 days of their first recorded COVID-19 event or a discharge destination denoting death after a COVID-19 hospitalisation (see Thygesen et al (<u>https://github.com/BHFDSC/CCU013_01_ENG-COVID-</u> <u>19_event_phenotyping/tree/main/phenotypes</u>) for further details and phenotyping algorithms). Follow-up for COVID-19 outcomes ended on 1st May 2021 with the final follow-up date as either the date of the outcome of interest (e.g. COVID-19 death) or the study end date (1st May 2021).

Covariates

Covariates were pre-selected based on potential associations with pre-existing AT use[6] or COVID-19 outcomes and included demographics (age, sex, ethnicity, geographic location, socio-economic status (as measured by index of multiple deprivation (IMD) decile)), comorbidities that increase stroke and bleeding risk (congestive heart failure, hypertension, stroke, vascular disease, diabetes, uncontrolled hypertension, renal disease, liver disease, prior major bleeding, hazardous alcohol use, history of fall, body mass index (BMI), smoking status) and other medications (anti-hypertensives, lipid-regulating drugs, proton pump inhibitors, NSAIDs, corticosteroids, other immunosuppressants and COVID-19 vaccination status, defined as at least one vaccine recorded in the COVID-19 vaccination events dataset prior to the individual's COVID-19 event).

The same covariates (excluding COVID-19 vaccination status) were used as independent variables to test associations with pre-existing AT use (for any AT vs no AT, AP only vs AC only, DOACs vs warfarin) and to calculate a propensity score for use as an additional covariate in the COVID-19 outcome analysis.

Statistical analysis

Descriptive statistics were used to summarise the study population characteristics and were stratified by medication category. Pairwise Pearson's correlation coefficients were used to check for potential collinearities between covariates. Multivariable logistic regression was used to test associations with pre-existing AT use and calculate the propensity score.

Multivariable logistic regression and Cox regression were used to test differences between exposure groups (any AT vs no AT, AC only vs AP only, DOACs vs warfarin) for COVID-19 related hospitalisation and death. These methods were selected to evaluate potential differences between event (logistic regression) and time-to-event (Cox regression) based analysis. All covariates including the propensity score were included in both methods. For variables with incomplete data (BMI – 9.3% missing), individual values were imputed with the cohort mean.

Two sensitivity analyses were conducted. Firstly, to evaluate the potential impact of different time periods, analysis was repeated for Jan 1st 2020 – December 1st 2020, prior to the introduction of vaccines and the December 29th 2020 cases peak of the second wave[14]. Secondly, to validate the potential effect on COVID-19 specific outcomes, analysis was repeated with COVID-19 hospitalisation and death defined exclusively as the primary recorded diagnosis (coded first in hospital record or death certificate).

Primary results are reported from the multivariable logistic regression models covering the full time period (Jan 1st 2020 – May 1st 2021) with the other analyses reviewed for concordance.

Data preparation was performed using Python 3.7 and Spark SQL (2.4.5) on Databricks Runtime 6.4 for Machine Learning with analysis performed using R version 4.0.3. All code for data preparation and analysis is available on Github (<u>https://github.com/BHFDSC/CCU020/tree/main/england/code</u>) and full results available at this microsite (<u>https://alexhandy1.shinyapps.io/at-evaluation-results/</u>)

Ethical and Regulatory Approvals

Data access approval was granted to the CVD-COVID-UK consortium through the NHS Digital online Data Access Request Service (ref. DARS-NIC-381078-Y9C5K). The BHF Data Science Centre approvals and oversight board deemed that this

project (proposal CCU020 Evaluation of antithrombotic use and COVID-19 outcomes) fell within the scope of the consortium's ethical and regulatory approvals. Analyses were conducted by approved researcher (AH) via secure remote access to the TRE. Only summarised, aggregate results were exported, following manual review by the NHS Digital 'safe outputs' escrow service, to ensure no output placed in the public domain contains information that may be used to identify an individual[12]. The North East-Newcastle and North Tyneside 2 research ethics committee provided ethical approval for the CVD-COVID-UK research programme (REC No 20/NE/0161).

RESULTS

Evaluation of antithrombotic use

From a total of 55,903,113 individuals registered with a GP practice in England, 972,971 (1.7%) had a diagnosis of AF and a CHA₂DS₂-VASc score>=2 on January 1st 2020 and 88.0% (n=856,336) had pre-existing AT use, with 74.3% (n=722,737) on AC only. The demographic and clinical characteristics of this cohort are summarised in *Tables 1-3*. By May 2021, the proportion of individuals on any AT had fallen to 87.7% but AC only had increased to 75.7% (see *Figure 2*). For individuals on any AT, warfarin prescriptions fell from 24.8% in January 2020 to 17.1% in May 2021 whilst DOACs rose from 60.3% to 69.5% (see *Supplementary Figure 2*).

Table 1 - study population demographic characteristics by antithromboticmedication category

Percentages should be interpreted vertically for all variables e.g. proportion within category for variable, except for the first row showing percentage of individuals across AT medication categories.

Any AT = any antithrombotic, AC only = anticoagulants only, AP only = antiplatelets only, AC and AP = anticoagulants and antiplatelets, no AT = no antithrombotic.

	Total	Any AT	AC only	AP only	AC and AP	No AT
Individuals	972971	856336	722737	70498	63101	116635
	(100%)	(88%)	(74.3%)	(7.2%)	(6.5%)	(12%)
Age (mean years, +/-	79 (+/-	79 (+/- 9)	79 (+/-	79 (+/-	78 (+/-	78 (+/-
sd)	9.3)		8.9)	10)	8.9)	11)
65-74	229464	198956	166943	16018	15995	30508
	(23.6%)	(23.2%)	(23.1%)	(22.7%)	(25.3%)	(26.2%)
>=75	686578	610497	518205	49702	42590	76081
	(70.6%)	(71.3%)	(71.7%)	(70.5%)	(67.5%)	(65.2%)

Female	449279	387184	338477	28622	20085	62095
	(46.2%)	(45.2%)	(46.8%)	(40.6%)	(31.8%)	(53.2%)
Ethnicity		(/	,		,	
White	932571	822292	696757	66237	59298	110279
	(95.8%)	(96%)	(96.4%)	(94%)	(94%)	(94.6%)
Asian or Asian British	20557	17699	12797	2536	2366	2858
	(2.1%)	(2.1%)	(1.8%)	(3.6%)	(3.7%)	(2.5%)
Black or Black British	9418	7658	6200	862	596	1760
	(1%)	(0.9%)	(0.9%)	(1.2%)	(0.9%)	(1.5%)
Mixed	3194	2636	2115	274	247	558
	(0.3%)	(0.3%)	(0.3%)	(0.4%)	(0.4%)	(0.5%)
Other Ethnic Groups	7231	6051	4868	589	594	1180
	(0.7%)	(0.7%)	(0.7%)	(0.8%)	(0.9%)	(1%)
Geographical locations						
South East	172714	150276	127207	11566	11503	22438
	(17.8%)	(17.5%)	(17.6%)	(16.4%)	(18.2%)	(19.2%)
North West	143391	127860	106990	10705	10165	15531
	(14.7%)	(14.9%)	(14.8%)	(15.2%)	(16.1%)	(13.3%)
East of England	104591	92676	78194	7408	7074	11915
	(10.7%)	(10.8%)	(10.8%)	(10.5%)	(11.2%)	(10.2%)
South West	108250	94816	80009	7863	6944	13434
	(11.1%)	(11.1%)	(11.1%)	(11.2%)	(11%)	(11.5%)
Yorkshire and The	108285	96113	81386	8405	6322	12172
Humber	(11.1%)	(11.2%)	(11.3%)	(11.9%)	(10%)	(10.4%)
West Midlands	111062	97555	83383	7836	6336	13507
	(11.4%)	(11.4%)	(11.5%)	(11.1%)	(10%)	(11.6%)
East Midlands	83786	74596	63978	5773	4845	9190
	(8.6%)	(8.7%)	(8.9%)	(8.2%)	(7.7%)	(7.9%)
London	95746	81824	66815	7495	7514	13922
	(9.8%)	(9.6%)	(9.2%)	(10.6%)	(11.9%)	(11.9%)
North East	45146	40620	34775	3447	2398	4526
	(4.6%)	(4.7%)	(4.8%)	(4.9%)	(3.8%)	(3.9%)
IMD deciles						
1 (most deprived)	78061	68894	56583	6490	5821	9167
	(8%)	(8%)	(7.8%)	(9.2%)	(9.2%)	(7.9%)

perpetuity. All rights reserved. No reuse allowed without permission.

10 (least deprived)	106436	93984	80764	6795	6425	12452
	(10.9%)	(11%)	(11.2%)	(9.6%)	(10.2%)	(10.7%)

Table 2 - study population comorbidities that increase stroke and bleeding risk by antithrombotic medication category

Percentages should be interpreted vertically for all variables e.g. proportion within category for variable. HAS-BLED score component bleeding medications excluded as measured within exposures and labile INR excluded as could not be accurately extracted from datasets.

	Total	Any AT	AC only	AP only	AC and AP	No AT
CHA2DS2-VASc score						
components						
Vascular disease	169797	159892	103946	23815	32131	9905
	(17.5%)	(18.7%)	(14.4%)	(33.8%)	(50.9%)	(8.5%)
Stroke / TIA /	196899	183140	150588	16611	15941	13759
Thromboembolism	(20.2%)	(21.4%)	(20.8%)	(23.6%)	(25.3%)	(11.8%)
Congestive heart failure	247562	228877	192023	15038	21816	18685
	(25.4%)	(26.7%)	(26.6%)	(21.3%)	(34.6%)	(16%)
Diabetes	268437	242060	197216	21602	23242	26377
	(27.6%)	(28.3%)	(27.3%)	(30.6%)	(36.8%)	(22.6%)
Hypertension	675676	600623	505514	49678	45431	75053
	(69.4%)	(70.1%)	(69.9%)	(70.5%)	(72%)	(64.3%)
CHA2DS2-VASc score	3.9 (+/-	4 (+/- 1.4)	3.9 (+/-	4.1 (+/-	4.4 (+/-	3.4 (+/-
(mean, +/- sd)	1.4)		1.4)	1.5)	1.5)	1.3)
2	172172	138750	120969	10912	6869	33422
	(17.7%)	(16.2%)	(16.7%)	(15.5%)	(10.9%)	(28.7%)
3	245979	213057	184241	16289	12527	32922
	(25.3%)	(24.9%)	(25.5%)	(23.1%)	(19.9%)	(28.2%)
4	252047	224255	190707	17875	15673	27792
	(25.9%)	(26.2%)	(26.4%)	(25.4%)	(24.8%)	(23.8%)
5	162318	149105	122356	12995	13754	13213
	(16.7%)	(17.4%)	(16.9%)	(18.4%)	(21.8%)	(11.3%)
>=6	140455	131169	104464	12427	14278	9286
	(14.4%)	(15.3%)	(14.5%)	(17.6%)	(22.6%)	(8%)
HAS-BLED score						
components						

	F = F =	
	N a warraa allariyaal yudda ay taaa	
All rights reserved	INO FEUSE Allowed without be	rmission
7 11 119110 100011000.	No reuse allowed without pe	

1	1			1	
315940	284379	237965	24423	21991	31561
(32.5%)	(33.2%)	(32.9%)	(34.6%)	(34.9%)	(27.1%)
8462	6707	5440	788	479	1755
(0.9%)	(0.8%)	(0.8%)	(1.1%)	(0.8%)	(1.5%)
196493	182756	150232	16606	15918	13737
(20.2%)	(21.3%)	(20.8%)	(23.6%)	(25.2%)	(11.8%)
335289	293096	240703	27431	24962	42193
(34.5%)	(34.2%)	(33.3%)	(38.9%)	(39.6%)	(36.2%)
28970	25572	21162	2274	2136	3398
(3%)	(3%)	(2.9%)	(3.2%)	(3.4%)	(2.9%)
66576	58873	48444	5395	5034	7703
(6.8%)	(6.9%)	(6.7%)	(7.7%)	(8%)	(6.6%)
119738	103615	85718	10717	7180	16123
(12.3%)	(12.1%)	(11.9%)	(15.2%)	(11.4%)	(13.8%)
28.7 (+/-	28.8 (+/-	28.8 (+/-	28.1 (+/-	29 (+/-	27.9 (+/-
6)	6)	6.1)	5.6)	5.8)	5.9)
638775	566860	472208	48567	46085	71915
(65.7%)	(66.2%)	(65.3%)	(68.9%)	(73%)	(61.7%)
	8462 (0.9%) 196493 (20.2%) 335289 (34.5%) 28970 (3%) 66576 (6.8%) 119738 (12.3%) 28.7 (+/- 6) 638775	(32.5%) (33.2%) 8462 6707 (0.9%) (0.8%) 196493 182756 (20.2%) (21.3%) 335289 293096 (34.5%) (34.2%) 28970 25572 (3%) (3%) 66576 58873 (6.8%) (6.9%) 119738 103615 (12.3%) (12.1%) 28.7 (+/- 28.8 (+/- 6) 6)	$\begin{array}{ccccccc} (32.5\%) & (33.2\%) & (32.9\%) \\ 8462 & 6707 & 5440 \\ (0.9\%) & (0.8\%) & (0.8\%) \\ 196493 & 182756 & 150232 \\ (20.2\%) & (21.3\%) & (20.8\%) \\ 335289 & 293096 & 240703 \\ (34.5\%) & (34.2\%) & (33.3\%) \\ & & & & & & \\ \end{array}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Table 3 – study population characteristics for COVID-19 outcomes and other medications by antithrombotic medication category

Percentages should be interpreted vertically for all variables e.g. proportion within category for variable. Pre-existing medication use was determined as >=1 dispensed prescription in the 6 months prior to the cohort start date (Jan 1st 2020).

	Total	Any AT	AC only	AP only	AC and AP	No AT
COVID-19 outcomes						
Any COVID-19 event	77364	67087	54756	6743	5588	10277
	(8%)	(7.8%)	(7.6%)	(9.6%)	(8.9%)	(8.8%)
COVID-19	37418	33150	26887	3201	3062	4268
hospitalisation	(3.8%)	(3.9%)	(3.7%)	(4.5%)	(4.9%)	(3.7%)
COVID-19	27011	23919	19375	2319	2225	3092
hospitalisation (primary	(2.8%)	(2.8%)	(2.7%)	(3.3%)	(3.5%)	(2.7%)
diagnosis)						
COVID-19 death	21116	18173	14553	2055	1565	2943
	(2.2%)	(2.1%)	(2%)	(2.9%)	(2.5%)	(2.5%)

	porporany.	
All rights record	ed. No reuse allowed without permission	
All fights reactiv	a. No rease allowed without permission	•

COVID-19 death	15297	13158	10522	1508	1128	2139
(primary diagnosis)	(1.6%)	(1.5%)	(1.5%)	(2.1%)	(1.8%)	(1.8%)
Other medications						
Antihypertensives	540678	498113	412077	40375	45661	42565
	(55.6%)	(58.2%)	(57%)	(57.3%)	(72.4%)	(36.5%)
Lipid regulating drugs	589568	547521	441736	51120	54665	42047
	(60.6%)	(63.9%)	(61.1%)	(72.5%)	(86.6%)	(36.1%)
Proton pump inhibitors	409429	369461	286984	39180	43297	39968
	(42.1%)	(43.1%)	(39.7%)	(55.6%)	(68.6%)	(34.3%)
NSAIDS	19448	14608	11101	2317	1190	4840
	(2%)	(1.7%)	(1.5%)	(3.3%)	(1.9%)	(4.1%)
Corticosteroids	80347	71706	59511	5929	6266	8641
	(8.3%)	(8.4%)	(8.2%)	(8.4%)	(9.9%)	(7.4%)
Other	13216	11690	9498	1152	1040	1526
immunosuppressants	(1.4%)	(1.4%)	(1.3%)	(1.6%)	(1.6%)	(1.3%)
COVID-19 vaccine prior	9463	8248	6799	824	625 (1%)	1215
to COVID-19 event	(1%)	(1%)	(0.9%)	(1.2%)		(1%)
	l					

Factors associated with pre-existing AT use vs no AT are shown in *Figure 3*. Lipid regulating drugs (OR=2.50 *[2.47-2.54 at 95% CI]*) and antihypertensives (OR=1.90 *[1.88-1.93 at 95% CI]*) were associated with the highest odds of pre-existing AT use followed by comorbidities in the CHA₂DS₂-VASc score (stroke (OR=1.76 *[1.72-1.79 at 95% CI]*, vascular disease (OR=1.60 *[1.56-1.63 at 95% CI]*). In contrast, nonsteroidal anti-Inflammatory drugs (NSAIDS, OR=0.39 *[0.37-0.40]*), liver disease (OR=0.56 *[0.53-0.59]*) and history of falls (OR=0.80 *[0.79-0.82]*) were associated with reduced odds.

Differences were also observed across demographics, ethnicity, socio-economic status and geographic location, with females (OR=0.91 *[0.90-0.92]*) and individuals from ethnic minorities and lower socio-economic positions associated with lower odds of AT use (e.g. ethnicity of black or black british vs white (OR=0.68 *[0.64-0.72]*). In other AT sub-types (AC vs AP and DOACs vs warfarin) results were broadly consistent (see *Supplementary Material Figures 3-4*), with the primary exception that vascular disease was associated with reduced odds of AC vs AP (OR=0.37 *[0.36-0.38*)]).

Antithrombotic use and COVID-19 outcomes

From 972,971 individuals that had a diagnosis of AF and a CHA₂DS₂-VASc score>=2 on January 1st 2020, 8% (n=77,364) had a recorded COVID-19 event, 3.8% (n=37,418) had a COVID-19 related hospitalisation and 2.2% (n=21,116) died when followed up to 1st May 2021. The summary characteristics of individuals with a recorded COVID-19 event are summarised in *Supplementary Tables 1-3*. Mean age

(81) and comorbidities (mean CHA2DS2-VASc score 4.2) were both marginally higher compared to the full cohort. The proportion of individuals with pre-existing AT use was also marginally lower at 86.7%, but otherwise demographic and clinical characteristics were consistent.

Pre-existing AT use was associated with lower odds of COVID-19 death (OR=0.92 *[0.87-0.96 at 95% CI]*), but higher odds of COVID-19 hospitalisation OR=1.20 *[1.15-1.26 at 95% CI]*) (see *Figure 4*). The same pattern was observed for AC vs AP (COVID-19 death (OR=0.93 [0.87-0.98]), COVID-19 hospitalisation (OR=1.17 [1.11-1.24])) but not for DOACs vs warfarin (COVID-19 death (OR=1.00 [0.95-1.05]), COVID-19 hospitalisation (OR=0.86 [0.82-0.89]).

These results were all directionally consistent across Cox regression analysis and the sensitivity analyses (see *Supplementary Material Figure* 5-7). Full results are available on this microsite (<u>https://alexhandy1.shinyapps.io/at-evaluation-results/</u>).

DISCUSSION

Main findings

This study of routinely collected healthcare data from 56 million individuals in England is the largest scale evaluation of AT use to date. In 972,971 individuals with AF and a CHA2DS2-VASc score>=2, we observed 88.0% (n=856,336) with preexisting AT use which was associated with marginal protection against COVID-19 death (OR=0.92 *[0.87-0.96 at 95% CI]*). Although this association may not be causal, it provides further incentive to improve AT coverage for eligible individuals with AF.

Of the AF cohort analysed, 8% (n=77,364) had a recorded COVID-19 event of which 3.8% (n=37,418) had a COVID-19 related hospitalisation and 2.2% (n=21,116) died. A marginally lower risk of COVID-19 death was observed for those with pre-existing AT use which directionally aligns with the most comparable previous studies[9,11]. AT use was, however, associated with higher odds of COVID-19 hospitalisation. This observation remained consistent when including only hospitalisations and deaths where COVID-19 was the first coded diagnosis. Higher observed risk of hospitalisation could reflect increased health seeking behaviour (both patient-driven or by a clinician) of those with pre-existing AT use or may indicate that any protective effect from AT materialises only in the most serious cases. The same pattern was observed in AC vs AP and supports the findings from Fröhlich et al that AC may offer more protection against death than AP[9]. For DOACs vs warfarin, no difference was observed between groups for COVID-19 hospitalisation. Our analysis did not directly

investigate the previously reported observation that vitamin K depletion through warfarin is harmful[15] but, more generally, our findings suggest that it is unlikely that warfarin offers protection against severe COVID-19 outcomes compared with DOACs[11].

Although these protective associations across AT sub-types do not prove causality, they provide further incentive to improve AT coverage for individuals with AF that are already at high risk of stroke. Previous evaluations in the UK have estimated that around 15% of these individuals do not take any AT and around 17% take AP only rather than the recommended AC[3,6]. Our evaluation found around 12% on no AT and around 7% on AP only which suggests national level guidance[16] and primary care incentives such as the Quality and Outcomes Framework [17] continue to have a positive impact. Nonetheless, one in five individuals remains on a sub-optimal medication regime. Shifts from warfarin to DOACs observed in this study and others[18] were recommended by COVID-19 guidance[19] and demonstrate the potential impact of rapidly disseminated medications policy using population scale EHR data.

Identifying which factors are associated with AT use is key to further lowering the proportion of individuals on sub-optimal medication. NSAIDs displayed the strongest association with no AT use and likely reflects the association between NSAIDs and increased risk of major bleeding in individuals with AF[20]. For comorbidities, liver disease had the strongest association with no AT use, which is also supported by clinical evidence[21]. However, recent evidence suggests[22,23] more personalised risk calculations for bleeding and stroke may enable more individuals with liver disease to benefit from AT. History of falls was the comorbidity with the second strongest association with no AT use suggesting it remains a key factor in AT medicating decisions and may be overweighted as a proxy for bleeding risk[7,24,25]. In the UK, NICE guidance was recently updated[4] to explicitly address this issue and it will be important to track the impact of this in future evaluations. On demographics, lower odds of AT use was observed in women but this is likely influenced by using NICE's primary threshold for the CHA2DS2-VASc score of 2 for both sexes. The CHA₂DS₂-VASc score allocates 1 point to females and 0 for males resulting in a larger proportion of comparatively health females (e.g. 12% and 25% of females in cohort have vascular disease or diabetes vs 21% and 33% respectively in males). However, demographic differences in AT use across ethnicity and socioeconomic status mirror systematic healthcare inequalities that have been reported previously[26,27]. Targeted outreach to these groups will be key to improving AT use further.

Strength and limitations

To our knowledge, this study is the largest scale evaluation of AT use to date. Routinely updated, linked, population-scale EHR datasets provide the statistical power to robustly analyse targeted sub-groups and control for a wide range of potential confounders. The prevalence of individuals with AF and CHA₂DS₂-VASc score>=2 in our cohort is similar to that observed in the Quality and Outcomes Framework[17] which provides an external validation for our dataset. All code is opensource and an updated nationwide evaluation can be rapidly created for future time points.

The study does have limitations. Firstly, the reported associations do not demonstrate causality and residual confounding is unlikely to have been fully eliminated. For example, in-hospital treatment regimens were not analysed so differences in COVID-19 outcomes due to additional targeted anticoagulation regimens[28] or other medications such as dexamethasone[29] cannot be accounted for in our analysis. Whilst we attempted to mitigate confounding through careful cohort selection, covariates and propensity score adjustment, our study design does not control for all potential factors associated with the initiation of AT use which may influence COVID-19 outcomes. Lastly, exposure to AT medication was defined as one or more dispensed prescriptions (recorded in NHS BSA Dispensed Medicines) in the previous 6 months. Other studies have used different time periods and prescription frequency counts[9,11] and adherence was not measured[30]. We purposefully defined a liberal threshold to support evaluation of AT usage up to May 2021 that may have included unusual buying patterns (e.g. bulk buying) caused by the pandemic. The trade-off is that for the COVID-19 outcome analyses it increases the probability of including a minority of "exposed" individuals who had ceased regular, pre-existing AT medication.

Conclusions

Pre-existing AT use may offer marginal protection against COVID-19 death, with AC offering more protection than AP. Although this association may not be causal, it provides further incentive to improve AT coverage for eligible individuals with AF.

ACKNOWLEDGMENTS

This work is carried out with the support of the BHF Data Science Centre led by HDR UK (BHF Grant no. SP/19/3/34678). This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research.

The views expressed are those of the authors and not necessarily those of the organisations listed. The funders of this work played no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

COMPETING INTERESTS

The authors have no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work. SH works as a data scientist and data curator for NHS Digital, which holds and processes the data.

FUNDING

The British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to Health Data Research (HDR) UK) funded co-development (with NHS Digital) of the trusted research environment, provision of linked datasets, data access, user software licences, computational usage, and data management and wrangling support, with additional contributions from the HDR UK data and connectivity component of the UK governments' chief scientific adviser's national core studies programme to coordinate national covid-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians.

AH is supported by research funding from the HDR UK text analytics implementation project.

AB is supported by research funding from the National Institute for Health Research (NIHR), British Medical Association, Astra-Zeneca, and UK Research and Innovation.

AW is supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005) and by core funding from UK MRC (MR/L003120/1), BHF (RG/13/13/30194; RG/18/13/33946), and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).

CT is supported by a UCL UKRI Centre for Doctoral Training in Al-enabled Healthcare studentship (EP/S021612/1), MRC Clinical Top-Up and a studentship from the NIHR Biomedical Research Centre at University College London Hospital NHS Trust.

DMB holds a UK Research and Innovation (UKRI) Fellowship as part of Health Data Research UK (HDRUK) MR/S00310X/1.

MAM is supported by research funding from Astra-Zeneca.

MK is funded by the British Heart Foundation (grant: FS/18/5/33319).

RD is supported by the following: (1) NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK; (2) Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust; (3) The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA; it is chaired by DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC; (4) the National Institute for Health Research University College London Hospitals Biomedical Research Centre; (5) the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London: (6) the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare; (7) the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust.

SD is supported by: (1) Health Data Research UK London, which receives its funding from HDR UK funded by the UK MRC, EPSRC, ESRC, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh government), Public Health Agency (Northern Ireland), BHF, and Wellcome Trust; (2) The NIHR Biomedical Research Centre at University College

All rights reserved. No reuse allowed without permission.

London Hospital NHS Trust; (3) The Alan Turing Institute (EP/N510129/1); (4) The British Heart Foundation Accelerator Award (AA/18/6/24223); (5) The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA; it is chaired by DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC.

AB, AW, RD and SD are part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074.

REFERENCES

- 1 Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *Int J Stroke* 2021;**16**:217–21. doi:10.1177/1747493019897870
- 2 Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. *Stroke* 2014;**45**:2599–605. doi:10.1161/STROKEAHA.114.006070
- 3 Campbell Cowan J, Wu J, Hall M, *et al.* A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. *Eur Heart J* 2018;**39**:2975–83. doi:10.1093/eurheartj/ehy411
- 4 NICE. Recommendations | Atrial fibrillation: diagnosis and management | Guidance | NICE. Published Online First: 2021.https://www.nice.org.uk/guidance/ng196/chapter/Recommendations#stro ke-prevention (accessed 30 Jun 2021).
- 5 Proietti M, Lane DA, Boriani G, *et al.* Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. *Can J Cardiol* 2019;**35**:619–33. doi:10.1016/J.CJCA.2019.02.009
- 6 Lacoin L, Lumley M, Ridha E, *et al.* Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: A cross-sectional analysis study using CPRD. *BMJ Open* 2017;**7**:e015363. doi:10.1136/bmjopen-2016-015363
- 7 Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleve. Clin. J. Med. 2017;**84**:35–40. doi:10.3949/ccjm.84a.16016
- 8 Yang H, Liang X, Xu J, *et al.* Meta-Analysis of Atrial Fibrillation in Patients With COVID-19. Am. J. Cardiol. 2021;**144**:152–6. doi:10.1016/j.amjcard.2021.01.010
- 9 Fröhlich GM, Jeschke E, Eichler U, *et al.* Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. *Clin Res Cardiol* 2021;:1–10. doi:10.1007/s00392-020-01783-x
- 10 Tremblay D, Van Gerwen M, Alsen M, *et al.* Impact of anticoagulation prior to

All rights reserved. No reuse allowed without permission.

COVID-19 infection: A propensity score-matched cohort study. Blood. 2020;**136**:144–7. doi:10.1182/BLOOD.2020006941


- 11 OpenSAFELY Collaborative T, Wong AY, Tomlinson L, *et al.* Association between oral anticoagulants and COVID-19 related outcomes: two cohort studies. *medRxiv* 2021;:2021.04.30.21256119. doi:10.1101/2021.04.30.21256119
- 12 Wood A, Denholm R, Hollings S, *et al.* Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: Data resource. *BMJ* 2021;**373**. doi:10.1136/bmj.n826
- Bjerring Olesen J, Torp-Pedersen C, Lock Hansen M, et al. New Technologies, Diagnostic Tools and Drugs The value of the CHA 2 DS 2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS 2 score 0-1: A nationwide cohort study. Published Online First: 2012. doi:10.1160/TH12-03-0175
- 14 Cases in the UK | Coronavirus in the UK. https://coronavirus.data.gov.uk/details/cases (accessed 30 Jun 2021).
- 15 Dofferhoff ASM, Piscaer I, Schurgers LJ, *et al.* Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019. *Clin Infect Dis* Published Online First: 27 August 2020. doi:10.1093/cid/ciaa1258
- 16 NICE. Atrial fibrillation: management | Guidance | NICE. *Https://WwwNiceOrgUk/Guidance/Cg180* Published Online First: 2014.https://www.nice.org.uk/guidance/cg180 (accessed 22 Jun 2021).
- 17 NHS Digital. QOF 2019-20 | NHS Digital. https://qof.digital.nhs.uk/ (accessed 30 Jun 2021).
- 18 Curtis HJ, MacKenna B, Walker AJ, *et al.* OpenSAFELY: Impact of national guidance on switching from warfarin to direct oral anticoagulants (DOACs) in early phase of COVID-19 pandemic in England. medRxiv. 2020;:2020.12.03.20243535. doi:10.1101/2020.12.03.20243535
- 19 NHS England. Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic. 31.03.2020.
 2020;:14.https://www.england.nhs.uk/coronavirus/publication/specialty-guides/%0Ahttps://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0077-Specialty-guide_Anticoagulant-services-and-coronavirus-v1-31-March.pdf (accessed 30 Jun 2021).
- Dalgaard F, Mulder H, Wojdyla DM, *et al.* Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. *Circulation* 2020;:10–20. doi:10.1161/CIRCULATIONAHA.119.041296
- 21 Søgaard KK, Horváth-Puhó E, Grønbæk H, *et al.* Risk of venous thromboembolism in patients with liver disease: A nationwide population-based case-control study. *Am J Gastroenterol* 2009;**104**:96–101. doi:10.1038/ajg.2008.34
- 22 Qamar A, Vaduganathan M, Greenberger NJ, *et al.* Oral Anticoagulation in Patients With Liver Disease. J. Am. Coll. Cardiol. 2018;**71**:2162–75. doi:10.1016/j.jacc.2018.03.023
- 23 Lee SR, Lee HJ, Choi EK, *et al.* Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. *J Am Coll Cardiol* 2019;**73**:3295–308. doi:10.1016/j.jacc.2019.04.052
- 24 Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants.

All rights reserved. No reuse allowed without permission.

In: *Journal of Thrombosis and Thrombolysis*. Springer 2013. 312–9. doi:10.1007/s11239-013-0899-7

- 25 Donzé J, Clair C, Hug B, *et al.* Risk of falls and major bleeds in patients on oral anticoagulation therapy. *Am J Med* 2012;**125**:773–8. doi:10.1016/j.amjmed.2012.01.033
- 26 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020;**584**:430–6. doi:10.1038/s41586-020-2521-4
- 27 Marmot M, Bell R. Fair society, healthy lives. *Public Health* 2012;**126**:S4. doi:10.1016/j.puhe.2012.05.014
- 28 Fauvel C, Weizman O, Trimaille A, et al. Pulmonary embolism in COVID-19 patients: A French multicentre cohort study. Eur Heart J 2020;41:3058–68. doi:10.1093/eurheartj/ehaa500
- 29 Group TRC. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021;**384**:693–704. doi:10.1056/nejmoa2021436
- 30 Banerjee A, Benedetto V, Gichuru P, *et al.* Original research: Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. *Heart* 2020;**106**:119. doi:10.1136/HEARTJNL-2019-315307

FIGURES



Abbreviations: Antithrombotics (AT), anticoagulants (AC), antiplatelets (AC), direct oral anticoagulants (DOACs), odds ratios (OR)

Figure 1: Illustrative overview of study design




Figure 2: Individual antithrombotic prescriptions by category January 2020 – May 2021

Ordered by proportion of prescriptions with mutually exclusive categories.




Figure 3: Factors associated with AT vs no AT medication (January 1st 2020) using multivariable logistic regression




Figure 4: Comparison of AT medication exposures on COVID-19 outcomes (follow up to May 1st 2021) using propensity score adjusted multivariable logistic regression

All rights reserved. No reuse allowed without permission.

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY TABLES

Supplementary Table 1 - study population demographic characteristics for individuals with COVID-19 event by antithrombotic medication category Percentages should be interpreted vertically for all variables e.g. proportion within category for variable, except for the first row showing percentage of individuals across AT medication categories.

	Total	Any AT	AC only	AP only	AC and AP	No AT
Individuals	77364	67087	54756	6743	5588	10277
	(100%)	(86.7%)	(70.8%)	(8.7%)	(7.2%)	(13.3%)
Age (mean years, +/- sd)	81 (+/-	81 (+/-	81 (+/-	82 (+/-	79 (+/-	81 (+/-
	10.1)	9.8)	9.7)	10.6)	9.7)	12)
65-74	12928	11331	9123	1014	1194	1597
	(16.7%)	(16.9%)	(16.7%)	(15%)	(21.4%)	(15.5%)
>=75	59369	51579	42348	5289	3942	7790
	(76.7%)	(76.9%)	(77.3%)	(78.4%)	(70.5%)	(75.8%)
Female	37227	31498	26569	2992	1937	5729
	(48.1%)	(47%)	(48.5%)	(44.4%)	(34.7%)	(55.7%)
Ethnicity						
White	72745	63132	51899	6162	5071	9613
	(94%)	(94.1%)	(94.8%)	(91.4%)	(90.7%)	(93.5%)
Asian or Asian British	2666	2311	1578	389	344	355
	(3.4%)	(3.4%)	(2.9%)	(5.8%)	(6.2%)	(3.5%)
Black or Black British	1010	844	645	118	81	166
	(1.3%)	(1.3%)	(1.2%)	(1.7%)	(1.4%)	(1.6%)
Mixed	281	238	187	24	27	43 (0.4%)
	(0.4%)	(0.4%)	(0.3%)	(0.4%)	(0.5%)	
Other Ethnic Groups	662	562	447	50	65	100 (1%)
	(0.9%)	(0.8%)	(0.8%)	(0.7%)	(1.2%)	
Geographical locations						
South East	11387	9725	8012	913	800	1662
	(14.7%)	(14.5%)	(14.6%)	(13.5%)	(14.3%)	(16.2%)
North West	12691	11153	9024	1113	1016	1538
	(16.4%)	(16.6%)	(16.5%)	(16.5%)	(18.2%)	(15%)
East of England	7095	6163	5047	591	525	932
	(9.2%)	(9.2%)	(9.2%)	(8.8%)	(9.4%)	(9.1%)

	porporany.	
All rights reserved	No reuse allowed without permission.	
/ 11 1191110 100011000.	no reace anonea mareat permission.	

		T	1	1	1	1 1
South West	4185	3577	2911	367	299	608
	(5.4%)	(5.3%)	(5.3%)	(5.4%)	(5.4%)	(5.9%)
Yorkshire and The	8809	7639	6230	878	531	1170
Humber	(11.4%)	(11.4%)	(11.4%)	(13%)	(9.5%)	(11.4%)
West Midlands	13273	11492	9423	1129	940	1781
	(17.2%)	(17.1%)	(17.2%)	(16.7%)	(16.8%)	(17.3%)
East Midlands	7279	6439	5376	603	460	840
	(9.4%)	(9.6%)	(9.8%)	(8.9%)	(8.2%)	(8.2%)
London	8806	7528	5929	802	797	1278
	(11.4%)	(11.2%)	(10.8%)	(11.9%)	(14.3%)	(12.4%)
North East	3839	3371	2804	347	220	468
	(5%)	(5%)	(5.1%)	(5.1%)	(3.9%)	(4.6%)
IMD deciles						
1 (most deprived)	8396	7331	5843	832	656	1065
	(10.9%)	(10.9%)	(10.7%)	(12.3%)	(11.7%)	(10.4%)
10 (least deprived)	6306	5449	4574	480	395	857
	(8.2%)	(8.1%)	(8.4%)	(7.1%)	(7.1%)	(8.3%)

Supplementary Table 2 - study population comorbidities that increase stroke and bleeding risk for individuals with COVID-19 event by antithrombotic medication category

Percentages should be interpreted vertically for all variables e.g. proportion within category for variable

	Total	Any AT	AC only	AP only	AC and AP	No AT
CHA2DS2-VASc score						
components						
Vascular disease	169797	159892	103946	23815	32131	9905
	(17.5%)	(18.7%)	(14.4%)	(33.8%)	(50.9%)	(8.5%)
Stroke / TIA /	196899	183140	150588	16611	15941	13759
Thromboembolism	(20.2%)	(21.4%)	(20.8%)	(23.6%)	(25.3%)	(11.8%)
Congestive heart failure	247562	228877	192023	15038	21816	18685
	(25.4%)	(26.7%)	(26.6%)	(21.3%)	(34.6%)	(16%)
Diabetes	268437	242060	197216	21602	23242	26377
	(27.6%)	(28.3%)	(27.3%)	(30.6%)	(36.8%)	(22.6%)
Hypertension	675680	600627	505516	49680	45431	75053
	(69.4%)	(70.1%)	(69.9%)	(70.5%)	(72%)	(64.3%)
CHA2DS2-VASc score	3.9 (+/-	4 (+/-	3.9 (+/-	4.1 (+/-	4.4 (+/-	3.4 (+/-
(mean, +/- sd)	1.4)	1.4)	1.4)	1.5)	1.5)	1.3)

			100000	40011		
2	172174	138751	120968	10914	6869	33423
	(17.7%)	(16.2%)	(16.7%)	(15.5%)	(10.9%)	(28.7%)
3	245977	213057	184242	16290	12525	32920
	(25.3%)	(24.9%)	(25.5%)	(23.1%)	(19.8%)	(28.2%)
4	252051	224259	190710	17874	15675	27792
	(25.9%)	(26.2%)	(26.4%)	(25.4%)	(24.8%)	(23.8%)
5	162315	149102	122353	12996	13753	13213
	(16.7%)	(17.4%)	(16.9%)	(18.4%)	(21.8%)	(11.3%)
>=6	140457	131171	104466	12426	14279	9286
	(14.4%)	(15.3%)	(14.5%)	(17.6%)	(22.6%)	(8%)
HAS-BLED score						
components						
Renal disease	315940	284379	237965	24423	21991	31561
	(32.5%)	(33.2%)	(32.9%)	(34.6%)	(34.9%)	(27.1%)
Liver disease	8462	6707	5440	788	479	1755
	(0.9%)	(0.8%)	(0.8%)	(1.1%)	(0.8%)	(1.5%)
Stroke	196493	182756	150232	16606	15918	13737
	(20.2%)	(21.3%)	(20.8%)	(23.6%)	(25.2%)	(11.8%)
Major bleeding event	335289	293096	240703	27431	24962	42193
	(34.5%)	(34.2%)	(33.3%)	(38.9%)	(39.6%)	(36.2%)
Harmful alcohol use	28969	25571	21161	2274	2136	3398
	(3%)	(3%)	(2.9%)	(3.2%)	(3.4%)	(2.9%)
Uncontrolled	66576	58873	48444	5395	5034	7703
hypertension	(6.8%)	(6.9%)	(6.7%)	(7.7%)	(8%)	(6.6%)
History of fall	119738	103615	85718	10717	7180	16123
	(12.3%)	(12.1%)	(11.9%)	(15.2%)	(11.4%)	(13.8%)
BMI (mean, +/- sd)	28.7 (+/-	28.8 (+/-	28.8 (+/-	28.1 (+/-	29 (+/-	27.9 (+/-
	6)	6)	6.1)	5.6)	5.8)	5.9)
Smoking status (ever	638774	566861	472208	48568	46085	71913
smoker)	(65.7%)	(66.2%)	(65.3%)	(68.9%)	(73%)	(61.7%)

Supplementary Table 3 – study population characteristics for COVID-19 outcomes and other medications for individuals with COVID-19 event by antithrombotic medication category


Percentages should be interpreted vertically for all variables e.g. proportion within category for variable

	Total	Any AT	AC only	AP only	AC and AP	No AT
COVID-19 outcomes						
COVID-19 event	77364	67087	54756	6743	5588	10277
	(8%)	(7.8%)	(7.6%)	(9.6%)	(8.9%)	(8.8%)

				-	-	
COVID-19	37418	33150	26887	3201	3062	4268
hospitalisation	(3.8%)	(3.9%)	(3.7%)	(4.5%)	(4.9%)	(3.7%)
COVID-19	27011	23919	19375	2319	2225	3092
hospitalisation (primary	(2.8%)	(2.8%)	(2.7%)	(3.3%)	(3.5%)	(2.7%)
diagnosis)						
COVID-19 death	21116	18173	14553	2055	1565	2943
	(2.2%)	(2.1%)	(2%)	(2.9%)	(2.5%)	(2.5%)
COVID-19 death	15297	13158	10522	1508	1128	2139
(primary diagnosis)	(1.6%)	(1.5%)	(1.5%)	(2.1%)	(1.8%)	(1.8%)
Other medications						
Antihypertensives	540681	498116	412078	40377	45661	42565
	(55.6%)	(58.2%)	(57%)	(57.3%)	(72.4%)	(36.5%)
Lipid regulating drugs	589570	547522	441737	51120	54665	42048
	(60.6%)	(63.9%)	(61.1%)	(72.5%)	(86.6%)	(36.1%)
Proton pump inhibitors	409430	369462	286984	39181	43297	39968
	(42.1%)	(43.1%)	(39.7%)	(55.6%)	(68.6%)	(34.3%)
NSAIDS	19448	14608	11101	2317	1190	4840
	(2%)	(1.7%)	(1.5%)	(3.3%)	(1.9%)	(4.1%)
Corticosteroids	80347	71706	59511	5929	6266	8641
	(8.3%)	(8.4%)	(8.2%)	(8.4%)	(9.9%)	(7.4%)
Other	13216	11690	9498	1152	1040	1526
immunosuppressants	(1.4%)	(1.4%)	(1.3%)	(1.6%)	(1.6%)	(1.3%)
COVID-19 vaccine prior	9463	8248	6799	824	625 (1%)	1215
to COVID-19 event	(1%)	(1%)	(0.9%)	(1.2%)		(1%)


All rights reserved. No reuse allowed without permission.

SUPPLEMENTARY FIGURES



Supplementary Figure 1: Cohort inclusion flowchart showing the number of individuals excluded at each step and the study population sizes for each question

All rights reserved. No reuse allowed without permission.




Time index

Supplementary Figure 2: Individual antithrombotic prescriptions by drug January 2020 – May 2021

Ordered by proportion of prescriptions with non-mutually exclusive categories e.g. an individual may have prescriptions for multiple drugs (warfarin and aspirin). Excludes drugs with <1% of prescriptions (ticagrelor, dipyridamole, prasugrel).


All rights reserved. No reuse allowed without permission.



Multivariable results for AC vs AP


Reference categories , 1) White 2) IMD decile 10 (least deprived) 3) South East

Supplementary Figure 3: Factors associated with AC vs AP (January 1st 2020) using multivariable logistic regression




Multivariable results for DOACS vs warfarin


Supplementary Figure 4: Factors associated with DOACs vs warfarin (January 1st 2020) using multivariable logistic regression



Supplementary Figure 5: Comparison of AT medication exposures on COVID-19 outcomes (follow up to May 1st 2021) using Cox regression



Supplementary Figure 6: Comparison of AT medication exposures on COVID-19 outcomes (follow up to December 1st 2020) using propensity score adjusted multivariable logistic regression



Supplementary Figure 7: Comparison of AT medication exposures on COVID-19 hospitalisation and death defined exclusively as the primary recorded diagnosis (follow up to May 1st 2021) using propensity score adjusted multivariable logistic regression